NURIX THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- NURIX THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-05-31 was $66.00K, a 1000.00% increase year-over-year.
- NURIX THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-02-28 was $375.00K, a 69.68% increase year-over-year.
- NURIX THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-08-31 was $178.00K, a 94.14% decline year-over-year.
- NURIX THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-05-31 was $6.00K, a 97.22% decline year-over-year.
- NURIX THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $1.65M, a 67.34% decline from fiscal 2024.
- NURIX THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $5.05M, a 412.68% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $986.00K, a 8.53% decline from fiscal 2022.
- NURIX THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $1.08M, a 35.29% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-05-31 | $66.00K 10-Q · filed 2026-07-09 | |
| 2026-02-28 | $375.00K 10-Q · filed 2026-07-09 | |
| 2025-11-30 | $1.65M 10-K · filed 2026-01-28 | |
| 2025-08-31 | $178.00K 10-Q · filed 2025-10-09 | |
| 2025-05-31 | $6.00K 10-Q · filed 2026-07-09 | |
| 2025-02-28 | $221.00K 10-Q · filed 2026-07-09 | |
| 2024-11-30 | $5.05M 10-K · filed 2026-01-28 | |
| 2024-08-31 | $3.04M 10-Q · filed 2025-10-09 | |
| 2024-05-31 | $216.00K 10-Q · filed 2025-10-09 | |
| 2024-02-29 | $355.00K 10-Q · filed 2025-10-09 | |
| 2023-11-30 | $986.00K 10-K · filed 2026-01-28 | |
| 2023-08-31 | $927.00K 10-Q · filed 2024-10-11 | |
| 2023-05-31 | $24.00K 10-Q · filed 2024-10-11 | |
| 2023-02-28 | $28.00K 10-Q · filed 2024-10-11 | |
| 2022-11-30 | $1.08M 10-K · filed 2025-01-28 | |
| 2022-08-31 | $174.00K 10-Q · filed 2023-10-12 | |
| 2022-05-31 | $432.00K 10-Q · filed 2023-10-12 | |
| 2022-02-28 | $424.00K 10-Q · filed 2023-10-12 | |
| 2021-11-30 | $1.67M 10-K · filed 2023-02-09 | |
| 2021-08-31 | $584.00K 10-Q · filed 2022-10-06 | |
| 2021-05-31 | $241.00K 10-Q · filed 2022-10-06 | |
| 2021-02-28 | $394.00K 10-Q · filed 2022-10-06 | |
| 2020-11-30 | $450.00K 10-K · filed 2022-01-28 | |
| 2020-08-31 | $262.00K 10-Q · filed 2021-10-14 | |
| 2020-05-31 | $118.00K 10-Q · filed 2021-10-14 | |
| 2020-02-29 | $37.00K 10-Q · filed 2021-10-14 | |
| 2019-11-30 | $104.00K 10-K · filed 2022-01-28 | |
| 2019-08-31 | $1.00K 10-Q · filed 2020-10-14 | |
| 2019-05-31 | $47.00K 10-Q · filed 2020-10-14 | |
| 2019-02-28 | $8.00K 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |